Safety Study of Hypothermia for Treatment of Hypoxic-Ischemic Brain Damage in Term Neonates

WH Zhou,XM Shao,Y Cao,C Chen,XD Zhang
IF: 7.169
2002-01-01
Acta Pharmacologica Sinica
Abstract:AIM: To investigate safety and efficacy of mild hypothermia by selective head cooling in term neonates with hypoxic-ischemic brain damage (HIBD). METHODS: Fifty term neonates with Apgar scores less than or equal to5 at 5 min, and/or evidence of encephalopathy within 6 h after birth, were randomized to either noncooling, normothermia (NORM, n=27), or mild hypothermia group (HYPO, n=23), in which head cooling was induced by circulating water for 72 h. Neurodevelopment outcome was assessed at 6 month. RESULTS: The heart rates of the HYPO at 24, 48, and 72 h after treatment dropped to 96+/-12, 85+/-9, and 96+/-16, whereas that of the NORM to 123+/-10, 125+/-13 and 121+/-19, respectively (P<0.05). There was no difference regarding ejection fraction (EF), stroke volume (SV) and cardiac output (CO) between the two groups [(0.61+/-0.04) vs (0.58+/-0.06), (2.3+/-0.5) vs (2.4+/-0.4) mL/kg, (256+/-54) vs (277+/-42) mL.kg(-1).min(-1), respectively]. D-dimmer and beta(2)MG were elevated in both groups. The neuron specific enolase (NSE) level of CSF was (26.2+/-10.8) mg/L in the HYPO and (34.6+/-17.1) mg/L in the NORM (P<0.05). Glutamic acid (GA) was lower in the HYPO [(2.4+/-0.8) vs (2.9+/-1.1) mmol/L, P<0.05]. The neurodevelopment outcome of the patients at 6 mo showed that 18 of 23 patients in the HYPO (78.3 %) were considered to have a normal developmental quotient (DQ) compared with 19 of 27 (70.4 %) in the NORM. CONCLUSION: The results of our pilot study suggest that mild hypothermia does not aggravate cardiac, kidney and coagulation function, but has a potential of neuroprotection, It warrants a randomized controlled clinical study to verify its efficacy in HIBD.
What problem does this paper attempt to address?